RESUMEN
The identification of HER2 alterations in advanced gastric carcinomas is of critical importance in daily clinical practice as such neoplasms require specific treatment with trastuzumab. For these reasons, pathologists and oncologists with expertise in gastric carcinomas and HER2 testing from both organisations (SEAP and SEOM) have endeavoured to discuss and agree on national guidelines for HER2 testing in gastric carcinomas. These guidelines are based on the experience of those who participated in the discussions and also on experience published internationally. These agreed guidelines give the minimum requirements that a pathological anatomy laboratory must fulfil in order to guarantee adequate HER2 testing in daily practice. Any laboratories which do not meet the minimum standards set out in the guidelines must make every effort to achieve compliance.
Asunto(s)
Carcinoma/genética , Consenso , Genes erbB-2 , Pruebas Genéticas/métodos , Pruebas Genéticas/estadística & datos numéricos , Neoplasias Gástricas/genética , Algoritmos , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Carcinoma/diagnóstico , Carcinoma/patología , Técnicas de Laboratorio Clínico/métodos , Ensayos Clínicos como Asunto , Genes erbB-2/genética , Humanos , Oncología Médica/legislación & jurisprudencia , Oncología Médica/métodos , Oncología Médica/organización & administración , Patología Molecular/legislación & jurisprudencia , Patología Molecular/métodos , Patología Molecular/organización & administración , Guías de Práctica Clínica como Asunto , Sociedades Médicas/legislación & jurisprudencia , España , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/patologíaRESUMEN
Identifying breast cancers with HER2 overexpression or amplification is critical as these usually imply the use of HER2-targeted therapies. DNA (amplification) and protein (overexpression) HER2 abnormalities usually occur simultaneously and both in situ hybridisation and immunohistochemistry may be accurate methods for the evaluation of these abnormalities. However, recent studies, including those conducted by the Association for Quality Assurance of the Spanish Society of Pathology, as well as the experience of a number of HER2 testing National Reference Centres have suggested the existence of serious reproducibility issues with both techniques. To address this issue, a joint committee from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) was established to review the HER2 testing guidelines. Consensus recommendations are based not only on the panellists' experience, but also on previous consensus guidelines from several countries, including the USA, the UK and Canada. These guidelines include the minimal requirements that pathology departments should fulfil in order to guarantee proper HER2 testing in breast cancer. Pathology laboratories not fulfilling these standards should make an effort to meet them and, until then, are highly encouraged to submit to reference laboratories breast cancer samples for which HER2 determination has clinical implications for the patients.